Beta Bionics (BBNX) Competitors

Beta Bionics logo
$13.35 -0.98 (-6.85%)
Closing price 03:59 PM Eastern
Extended Trading
$13.09 -0.26 (-1.91%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BBNX vs. AXGN, TMDX, IRTC, ATRC, and ESTA

Should you buy Beta Bionics stock or one of its competitors? Beta Bionics's main competitors and comparable companies include AxoGen (AXGN), TransMedics Group (TMDX), iRhythm Technologies (IRTC), AtriCure (ATRC), and Establishment Labs (ESTA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Beta Bionics compare to AxoGen?

Beta Bionics (NASDAQ:BBNX) and AxoGen (NASDAQ:AXGN) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

Beta Bionics presently has a consensus target price of $23.69, suggesting a potential upside of 77.50%. AxoGen has a consensus target price of $58.67, suggesting a potential upside of 4.19%. Given Beta Bionics' higher probable upside, equities research analysts plainly believe Beta Bionics is more favorable than AxoGen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Beta Bionics
1 Sell rating(s)
4 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.67
AxoGen
1 Sell rating(s)
2 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.75

AxoGen has higher revenue and earnings than Beta Bionics. AxoGen is trading at a lower price-to-earnings ratio than Beta Bionics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beta Bionics$100.25M7.24-$73.20M-$1.84N/A
AxoGen$225.21M14.93-$15.70M-$0.65N/A

Beta Bionics has a beta of 3.44, suggesting that its stock price is 244% more volatile than the broader market. Comparatively, AxoGen has a beta of 1.21, suggesting that its stock price is 21% more volatile than the broader market.

AxoGen has a net margin of -11.96% compared to Beta Bionics' net margin of -65.31%. AxoGen's return on equity of -5.35% beat Beta Bionics' return on equity.

Company Net Margins Return on Equity Return on Assets
Beta Bionics-65.31% -27.33% -24.28%
AxoGen -11.96%-5.35%-4.41%

In the previous week, Beta Bionics had 1 more articles in the media than AxoGen. MarketBeat recorded 8 mentions for Beta Bionics and 7 mentions for AxoGen. Beta Bionics' average media sentiment score of 0.70 beat AxoGen's score of 0.56 indicating that Beta Bionics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Beta Bionics
3 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
AxoGen
2 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

80.3% of AxoGen shares are owned by institutional investors. 5.3% of Beta Bionics shares are owned by company insiders. Comparatively, 2.4% of AxoGen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

AxoGen beats Beta Bionics on 10 of the 16 factors compared between the two stocks.

How does Beta Bionics compare to TransMedics Group?

TransMedics Group (NASDAQ:TMDX) and Beta Bionics (NASDAQ:BBNX) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings and dividends.

TransMedics Group presently has a consensus target price of $113.30, indicating a potential upside of 20.51%. Beta Bionics has a consensus target price of $23.69, indicating a potential upside of 77.50%. Given Beta Bionics' stronger consensus rating and higher probable upside, analysts plainly believe Beta Bionics is more favorable than TransMedics Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TransMedics Group
0 Sell rating(s)
7 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.42
Beta Bionics
1 Sell rating(s)
4 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.67

TransMedics Group has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TransMedics Group$605.49M5.39$190.29M$3.6925.48
Beta Bionics$100.25M7.24-$73.20M-$1.84N/A

TransMedics Group has a beta of 2.14, indicating that its stock price is 114% more volatile than the broader market. Comparatively, Beta Bionics has a beta of 3.44, indicating that its stock price is 244% more volatile than the broader market.

TransMedics Group has a net margin of 19.85% compared to Beta Bionics' net margin of -65.31%. TransMedics Group's return on equity of 13.30% beat Beta Bionics' return on equity.

Company Net Margins Return on Equity Return on Assets
TransMedics Group19.85% 13.30% 4.93%
Beta Bionics -65.31%-27.33%-24.28%

In the previous week, Beta Bionics had 5 more articles in the media than TransMedics Group. MarketBeat recorded 8 mentions for Beta Bionics and 3 mentions for TransMedics Group. Beta Bionics' average media sentiment score of 0.70 beat TransMedics Group's score of 0.28 indicating that Beta Bionics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
TransMedics Group
0 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Beta Bionics
3 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

99.7% of TransMedics Group shares are owned by institutional investors. 6.9% of TransMedics Group shares are owned by insiders. Comparatively, 5.3% of Beta Bionics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

TransMedics Group and Beta Bionics tied by winning 8 of the 16 factors compared between the two stocks.

How does Beta Bionics compare to iRhythm Technologies?

iRhythm Technologies (NASDAQ:IRTC) and Beta Bionics (NASDAQ:BBNX) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

iRhythm Technologies currently has a consensus target price of $164.07, indicating a potential upside of 74.10%. Beta Bionics has a consensus target price of $23.69, indicating a potential upside of 77.50%. Given Beta Bionics' higher possible upside, analysts plainly believe Beta Bionics is more favorable than iRhythm Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
iRhythm Technologies
1 Sell rating(s)
2 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.82
Beta Bionics
1 Sell rating(s)
4 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.67

iRhythm Technologies has a net margin of -4.52% compared to Beta Bionics' net margin of -65.31%. iRhythm Technologies' return on equity of 26.88% beat Beta Bionics' return on equity.

Company Net Margins Return on Equity Return on Assets
iRhythm Technologies-4.52% 26.88% 4.32%
Beta Bionics -65.31%-27.33%-24.28%

iRhythm Technologies has a beta of 1.39, meaning that its share price is 39% more volatile than the broader market. Comparatively, Beta Bionics has a beta of 3.44, meaning that its share price is 244% more volatile than the broader market.

In the previous week, iRhythm Technologies had 4 more articles in the media than Beta Bionics. MarketBeat recorded 12 mentions for iRhythm Technologies and 8 mentions for Beta Bionics. Beta Bionics' average media sentiment score of 0.70 beat iRhythm Technologies' score of 0.67 indicating that Beta Bionics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
iRhythm Technologies
2 Very Positive mention(s)
6 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Beta Bionics
3 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

iRhythm Technologies has higher revenue and earnings than Beta Bionics. iRhythm Technologies is trading at a lower price-to-earnings ratio than Beta Bionics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
iRhythm Technologies$747.14M4.24-$44.55M-$1.17N/A
Beta Bionics$100.25M7.24-$73.20M-$1.84N/A

Summary

iRhythm Technologies beats Beta Bionics on 9 of the 13 factors compared between the two stocks.

How does Beta Bionics compare to AtriCure?

AtriCure (NASDAQ:ATRC) and Beta Bionics (NASDAQ:BBNX) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.

AtriCure has a net margin of 2.52% compared to Beta Bionics' net margin of -65.31%. AtriCure's return on equity of 4.01% beat Beta Bionics' return on equity.

Company Net Margins Return on Equity Return on Assets
AtriCure2.52% 4.01% 3.03%
Beta Bionics -65.31%-27.33%-24.28%

99.1% of AtriCure shares are held by institutional investors. 4.0% of AtriCure shares are held by company insiders. Comparatively, 5.3% of Beta Bionics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Beta Bionics had 2 more articles in the media than AtriCure. MarketBeat recorded 8 mentions for Beta Bionics and 6 mentions for AtriCure. Beta Bionics' average media sentiment score of 0.70 beat AtriCure's score of 0.22 indicating that Beta Bionics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AtriCure
1 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Beta Bionics
3 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

AtriCure currently has a consensus price target of $62.30, suggesting a potential upside of 15.14%. Beta Bionics has a consensus price target of $23.69, suggesting a potential upside of 77.50%. Given Beta Bionics' stronger consensus rating and higher possible upside, analysts plainly believe Beta Bionics is more favorable than AtriCure.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AtriCure
1 Sell rating(s)
4 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.58
Beta Bionics
1 Sell rating(s)
4 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.67

AtriCure has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AtriCure$534.53M5.15-$11.45M$0.30180.37
Beta Bionics$100.25M7.24-$73.20M-$1.84N/A

AtriCure has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market. Comparatively, Beta Bionics has a beta of 3.44, meaning that its share price is 244% more volatile than the broader market.

Summary

Beta Bionics beats AtriCure on 8 of the 15 factors compared between the two stocks.

How does Beta Bionics compare to Establishment Labs?

Beta Bionics (NASDAQ:BBNX) and Establishment Labs (NASDAQ:ESTA) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

Beta Bionics presently has a consensus target price of $23.69, indicating a potential upside of 77.50%. Establishment Labs has a consensus target price of $95.00, indicating a potential upside of 36.47%. Given Beta Bionics' higher possible upside, equities analysts clearly believe Beta Bionics is more favorable than Establishment Labs.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Beta Bionics
1 Sell rating(s)
4 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.67
Establishment Labs
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.80

Establishment Labs has a net margin of -14.56% compared to Beta Bionics' net margin of -65.31%. Beta Bionics' return on equity of -27.33% beat Establishment Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
Beta Bionics-65.31% -27.33% -24.28%
Establishment Labs -14.56%-196.38%-10.45%

In the previous week, Beta Bionics had 8 more articles in the media than Establishment Labs. MarketBeat recorded 8 mentions for Beta Bionics and 0 mentions for Establishment Labs. Beta Bionics' average media sentiment score of 0.70 beat Establishment Labs' score of 0.00 indicating that Beta Bionics is being referred to more favorably in the media.

Company Overall Sentiment
Beta Bionics Positive
Establishment Labs Neutral

Establishment Labs has higher revenue and earnings than Beta Bionics. Establishment Labs is trading at a lower price-to-earnings ratio than Beta Bionics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beta Bionics$100.25M7.24-$73.20M-$1.84N/A
Establishment Labs$211.08M9.83-$51.06M-$1.28N/A

72.9% of Establishment Labs shares are held by institutional investors. 5.3% of Beta Bionics shares are held by insiders. Comparatively, 10.0% of Establishment Labs shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Beta Bionics has a beta of 3.44, indicating that its share price is 244% more volatile than the broader market. Comparatively, Establishment Labs has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market.

Summary

Establishment Labs beats Beta Bionics on 9 of the 15 factors compared between the two stocks.

Get Beta Bionics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BBNX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BBNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BBNX vs. The Competition

MetricBeta BionicsHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$779.08M$5.92B$7.59B$11.70B
Dividend YieldN/A1.69%2.48%4.65%
P/E RatioN/A35.5231.9526.73
Price / Sales7.245.328.415.55
Price / CashN/A23.4220.7221.66
Price / Book1.814.154.423.65
Net Income-$73.20M$143.14M$3.51B$394.00M
7 Day Performance-19.15%-5.25%-6.16%-6.39%
1 Month Performance-20.74%-5.76%-7.05%-8.77%
1 Year Performance-51.85%-1.61%-2.52%-8.48%

Beta Bionics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BBNX
Beta Bionics
3.3238 of 5 stars
$13.35
-6.9%
$23.69
+77.5%
-47.1%$779.08M$100.25MN/A423
AXGN
AxoGen
2.01 of 5 stars
$55.93
+1.0%
$57.92
+3.6%
+137.2%$3.31B$225.21MN/A622
TMDX
TransMedics Group
3.2014 of 5 stars
$91.38
-0.7%
$113.30
+24.0%
-17.6%$3.20B$605.49M50.55898
IRTC
iRhythm Technologies
4.3199 of 5 stars
$91.91
-1.8%
$164.07
+78.5%
-44.1%$3.15B$747.14M69.822,400
ATRC
AtriCure
2.5288 of 5 stars
$56.84
+1.5%
$62.30
+9.6%
+67.2%$2.85B$534.53M136.541,350

Related Companies and Tools


This page (NASDAQ:BBNX) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners